《新股表現》健倍苗苗(02161.HK)暗盤高開近17%報1.4元
根據輝立交易平台顯示,明天掛牌的健倍苗苗(02161.HK)暗盤高開近17%報1.4元,高低見1.47元/1.33元,現造1.44元,較上市價1.2元,升20%,成交100萬股。
由雅各臣(02633.HK)分拆上市的健倍苗苗,為總部設於香港的領先品牌醫療保健品推廣及分銷公司,其產品據點遍及大中華、東南亞和其他選定國家。是次上市以每股1.2元合共發售4,468.6萬股,公開發售獲約21.5倍超購,認購一手中籤率僅8%,料集資淨額約1,060萬元,主要用於為品牌中藥組合開發與品牌管理提供資金,以及用作發展第三方品牌產品組合增長策略一部分,為從第三方品牌擁有人獲得更多分銷權的付款提供資金等。上市獨家保薦人為銀河國際證券(香港)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.